Study on Immune Response After Honeybee Venom Immunotherapy
Author Information
Author(s): Ajda Demšar Luzar, Matija Rijavec, Mitja Košnik, Urška Bidovec-Stojković, Jerneja Debeljak, Mihaela Zidarn, Peter Kopač, Peter Korošec
Primary Institution: University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia
Hypothesis
Are humoral and cellular biomarkers associated with the success of honeybee venom immunotherapy?
Conclusion
The study found that only high basophil sensitivity before treatment and systemic adverse events during treatment were significantly associated with treatment failure.
Supporting Evidence
- 80% of patients showed successful treatment after a controlled sting challenge.
- High basophil sensitivity before treatment was linked to treatment failure.
- Systemic adverse events during treatment were observed in all patients with treatment failure.
Takeaway
This study looked at how the body reacts to honeybee venom treatment and found that some tests can help predict if the treatment will work.
Methodology
The study evaluated blood biomarkers of 25 patients undergoing honeybee venom immunotherapy and assessed treatment success through a controlled sting challenge one year after treatment.
Limitations
The study had a relatively small number of patients with treatment failure.
Participant Demographics
25 patients with Hymenoptera venom allergy, median age 49 years.
Statistical Information
P-Value
0.0055
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website